RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. Barua D, Sultana A, Islam MN, Cox F, et al. BMC Cancer 2023;23:288.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Barua D, Sultana A, Islam MN, Cox F, et al. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. BMC Cancer 2023;23:288.
PMID: 36997866